This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

M&A - Novo Nordisk - Metsera

Novo Nordisk has bid to buy Metsera, an obesity startup company, as part of a two-step proposal at $77.75 per share, a total of approximately $9.1 billion. Metsera was previously set to be acquired by Pfizer for approximately $4.9 billion.


To add details to this case file regarding legal or economic representatives, please contact editors@mlex.com

Timeline

Parties

Get the inside track, with MLex

With a global network of expert journalists digging deep into the areas of risk that matter to your business and clients—and the highest standards of impartiality—you can have complete trust in MLex to keep you ahead of the regulatory curve.


  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from specialists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

TRY MLEX FREE FOR 14 DAYS

View the parties now

Already a subscriber? Click here to login